Alimera Sciences To Present At Oppenheimer 23rd Annual Healthcare Conference

 Alimera Sciences To Present At Oppenheimer 23rd Annual Healthcare Conference

PR Newswire

ATLANTA, Dec. 3, 2012

ATLANTA, Dec. 3, 2012 /PRNewswire/ --Alimera Sciences, Inc. (Nasdaq: ALIM)
("Alimera"), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that Dan Myers, president and chief executive officer, will
present at the Oppenheimer 23^rd Annual Healthcare Conference at 4:30 P.M. ET
on Wednesday, December 12, 2012 at The Waldorf Astoria Hotel in New York City.

The presentation will be webcast live and can be accessed on the Investor
Relations section of the corporate website at http://www.alimerasciences.com.
For those who are not available to listen to the live broadcast, the webcast
will be archived for 90 days.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Alimera Sciences Limited, based in
London, is headquarters of the company's European operations. Presently
Alimera is focused on diseases affecting the back of the eye, or retina. Its
primary product, ILUVIEN, is an intravitreal implant containing fluocinolone
acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy
in the treatment of ocular disease.

ICR, LLC

for Alimera Sciences

John Mills

310-954-1105

John.Mills@icrinc.com

SOURCE Alimera Sciences, Inc.

Website: http://www.alimerasciences.com
 
Press spacebar to pause and continue. Press esc to stop.